Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer
Re-Induction of a Systemic Immune Response After Initial Response With Immune Therapy With Radiotherapy in Metastatic or Locally Recurrent Lung Cancer
Sponsor: Maastricht Radiation Oncology
A PHASE2 clinical study on Non-Small Cell Carcinoma of Lung, TNM Stage 4, this trial is completed. The trial is conducted by Maastricht Radiation Oncology and has accumulated 13 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2022 — May 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2021 — Sep 2022 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Feb 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Maastricht Radiation Oncology
- Maastricht University Medical Center
- The Netherlands Cancer Institute
- Zuyderland Medical Centre
For direct contact, visit the study record on ClinicalTrials.gov .